Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 81-87

  Mathijssen, Ron H J ^a   Verweij, Jaap ^a   De Jonge, Maja J A ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; BODY SIZE; BODY SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METABOLITE; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY CONSTITUTION; BODY SURFACE AREA; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; RETROSPECTIVE STUDIES;

EID: 0036137897     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.81     Document Type: Article

References (50)

1. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography
2. Irinotecan in the treatment of colorectal cancer: Clinical overview
3. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
4. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
5. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
6. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
7. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
8. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
9. Modulation of camptothecin analogs in the treatment of cancer: A review
10. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin
11. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors
12. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
13. Modulation of irinotecan-induced diarrhea by co-treatment with neomycin in patients with metastatic colorectal cancer
14. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
15. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
16. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11
17. Irinotecan metabolism and disposition in cancer patients
18. A formula to estimate the approximate surface area if height and weight be known
19. Lean body mass as a predictor of drug dosage
20. The impact of obesity and disease on busulfan oral clearance in adults
21. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
22. Body-surface area as a basis for dosing anticancer agents: Science, myth or habit?
23. Body surface area as a determinant of pharmacokinetics and drug dosing
24. Is dose normalization to weight or body surface area useful in adults?
25. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
26. Lean body mass, body surface area and epirubicin kinetics
27. What is the effect of adjusting epirubicin doses for body surface area?
28. Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens
29. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
30. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
31. Body mass index (BMI) is an independent predictor of peak plasma concentration (Cmax) of irinotecan (CPT-11)
32. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients
33. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
34. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
35. Gender-dependent pharmacokinetics of topotecan in adult patients
36. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer
37. Age as a risk factor in irinotecan (CPT-11) treatment of 5-FU-refractory colorectal cancer
38. Total plasma clearance of irinotecan (CPT-11) correlates with both alkaline phosphatase and bilirubin levels in patients with tumoral hepatic involvement
39. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: A need for guidelines
40. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
41. A family of drug transporters: The multidrug resistance-associated proteins
42. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promotor in human populations and primates
43. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
44. Gilbert's syndrome and hyperbilirubinaemia in ABO-incompatible neonates
45. Glucuronidation in humans: Pharmacogenetic and developmental aspects
46. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype
47. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4* 1B5′-promotor region polymorphism
48. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
49. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
50. Overview of recent topics in clinical pharmacology of anticancer agents